Search Videos and More
News
Dana-Farber Research News 04.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 through March 31.
News
Novel Genomic Screening Tool Enables Precision Reverse-Engineering of Genetic Programming in Cells
Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a novel approach to understanding how certain proteins called transcription factors determine which genetic programs will drive cell growth and maturation.
News
Dana-Farber Research News 04.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 1 through March 15.
News
FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research
FDA decision establishes cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors
News
Potential Targeted Therapy for Pediatric Brain Cancer Identified by Dana-Farber/Boston Children's Team
An international team of clinical collaborators, led by physician scientists from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma.
News
AI Learns Genomic “Language” to Advance Cancer Treatment
The human genome is a sequence of Ts, Gs, Cs, and As that is about 3 billion letters long. And, says Bradley Bernstein, MD, PhD, chair of Dana-Farber’s Department of Cancer Biology, “there’s no dictionary or guide for reading it.”
News
Treatment of Recurrent Endometrial Cancer with Metformin, Letrozole, and Abemaciclib is Safe and Promising, Dana-Farber Research Shows
A combination, triplet therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in nearly all patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer, results from a recent phase 2 clinical trial show.
News
Dana-Farber Research News 03.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 16 through February 28.
News
Novel Approaches in Waldenström's Macroglobulinemia
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium, on February 13-15, 2025, in San Francisco, Calif.
News
Novel Stem Cell Therapy Safely Repairs Irreversible Corneal Damage in Clinical Trial
An expanded phase clinical trial that tested a groundbreaking, experimental stem cell treatment for blinding cornea injuries found the treatment was feasible and safe in 14 patients who were treated and followed for 18 months, and there was a high proportion of complete or partial success.
News
Mind and Body: Prioritizing Mental Health
A lump felt in the shower. Weight loss. Night sweats. The anticipation — refreshing the portal for results, awaiting a phone call, wondering if your life will change in an instant.
Video
Kidney Cancer Conference Highlights from ASCO GU 2025
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates, focused on clear cell renal cell carcinoma (ccRCC), you need to know from GU ASCO 2025.